ReviewInternational journal of nanomedicine2020
A Review on the Biodistribution, Pharmacokinetics and Toxicity of Bismuth-Based Nanomaterials.
Review in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Nanoparticle radiosensitizers in cancer radiotherapy: bridging preclinical promise and clinical reality.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Gold decorated bismuth sulfide nanorods for enhanced computed tomography imaging with in vitro and in vivo validation.Discover nano · 2026Article
- From Innate Immunity to Cancer Therapy: Antimicrobial Peptides as Emerging Anticancer Agents.International journal of molecular sciences · 2026Review
- Traces of Elements in the Electrochemical Reductive Amination of Acetone: Uncovering Bi as Substitute for Pb.Angewandte Chemie (International ed. in English) · 2026Article
- Engineering Biocompatible Glutathione-Capped CuMaterials (Basel, Switzerland) · 2026Article
- Multifunctional Bismuth Nanoplatforms Augment Radioactive Iodine Therapy in Anaplastic Thyroid Cancer.International journal of nanomedicine · 2026Article
- Proteomic Changes in the Cytoplasmatic Fraction of Weaned Piglets' Liver and Kidney Under Antioxidant and Mycotoxin Diets.Antioxidants (Basel, Switzerland) · 2025Article
- Review
- Delivery of an ERK inhibitor using bioactive lipid nanoparticles reduces angiogenesis and prevents oral squamous cell carcinoma development.Journal of nanobiotechnology · 2025Article
- Recent Progress of Nanomedicine for the Synergetic Treatment of Radiotherapy (RT) and Photothermal Treatment (PTT).Cancers · 2025Review
- Nanoscale Porphyrin-Based Metal-Organic Frameworks for Enhanced Radiotherapy-Radiodynamic Therapy: A Comprehensive Review.Pharmaceutics · 2025Review
- Nanoparticles in the battle against Candida auris biofilms: current advances and future prospects.Drug delivery and translational research · 2025Review
- Bismuth-infused perivascular wrap facilitates delivery of mesenchymal stem cells and attenuation of neointimal hyperplasia in rat arteriovenous fistulas.Biomaterials advances · 2025Article
- A Polyurethane Electrospun Membrane Loaded with Bismuth Lipophilic Nanoparticles (BisBAL NPs): Proliferation, Bactericidal, and Antitumor Properties, and Effects on MRSA and Human Breast Cancer Cells.Journal of functional biomaterials · 2024Article
- Electrochemical Detection of HNanomaterials (Basel, Switzerland) · 2024Article
- Smart delivery vehicles for cancer: categories, unique roles and therapeutic strategies.Nanoscale advances · 2024Review
- Bioactive Bismuth Compounds: Is Their Toxicity a Barrier to Therapeutic Use?International journal of molecular sciences · 2024Review
- Non-invasive fast assessment of hepatic injury through computed tomography imaging with renal-clearable Bi-DTPA dimeglumine.Regenerative biomaterials · 2024Article
- A review of bismuth-based nanoparticles and their applications in radiosensitising and dose enhancement for cancer radiation therapy.IET nanobiotechnology · 2023Review
- Tween-20-Modified BiVOACS omega · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here, bismuth-based nanomaterials (Bi-based NMs) are introduced as promising theranostic agents to enhance image contrast as well as for the therapeutic gain for numerous diseases. However, understanding the interaction of such novel developed nanoparticles (NPs) within a biological environment is a requisite for the translation of any promising agent from the lab bench to the clinic. This interaction delineates the fate of NPs after circulation in the body. In an ideal setting, a nano-based therapeutic agent should be eliminated via the renal clearance pathway, meanwhile it should have specific targeting to a diseased organ to reach an effective dose and also to overcome off-targeting. Due to their clearance pathway, biodistribution patterns and pharmacokinetics (PK), Bi-based NMs have been found to play a determinative role to pass clinical approval and they have been investigated extensively in vivo to date. In this review, we expansively discuss the possible toxicity induced by Bi-based NMs on cells or organs, as well as biodistribution profiles, PK and the clearance pathways in animal models. A low cytotoxicity of Bi-based NMs has been found in vitro and in vivo, and along with their long-term biodistribution and proper renal clearance in animal models, the translation of Bi-based NMs to the clinic as a useful novel theranostic agent is promising to improve numerous medical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.